Journal List > Allergy Asthma Respir Dis > v.5(3) > 1059251

Cho, Kim, Lee, Choi, Kim, and Hong: Accuracy for registration of disease codes in pediatric anaphylaxis

Abstract

Purpose

The aim of this study was to survey the accuracy of registration as anaphylaxis codes and the clinical characteristics of anaphylaxis registered correctly and incorrectly in pediatric anaphylaxis.

Methods

This study was conducted retrospectively using the medical records of patients under 15 years who visited a training hospital Emergency Department (ED) for 5 years. The study subjects were divided into the correct group (registered as anaphylaxis codes correctly) and the incorrect group (registered as other anaphylaxis related codes).

Results

Of the 133 patients, 14 belonged to the correct group and 119 to the incorrect group. The median age of the correct group was 9 years old and that of the incorrect group was 2 years old. Sex, transportation to the ED, elapsed time from exposure to ED arrival, past history of allergy, causes of anaphylaxis except drug, severity of symptom, mental status, and antihistamine use were not different between the 2 groups. Drugs as the cause of anaphylaxis and cardiovascular/neurologic symptoms were more common in the correct group. Gastrointestinal symptoms were more frequent in the incorrect group. Intravenous fluid, steroid, bronchodilator, and epinephrine were more commonly used as the treatment for anaphylaxis in the correct group. The pediatric patients treated with epinephrine tended to be registered anaphylaxis correctly.

Conclusion

More patients were registered incorrectly as other anaphylaxis-related disease codes rather than correctly as the anaphylaxis disease codes in pediatric anaphylaxis. Epinephrine use was the associated factor for being registered correctly as the anaphylaxis disease codes in pediatric anaphylaxis.

REFERENCES

1. Johansson SG, Bieber T, Dahl R, Friedmann PS, Lanier BQ, Lockey RF, et al. Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol. 2004; 113:832–6.
crossref
2. Sampson HA, Muñoz-Furlong A, Campbell RL, Adkinson NF Jr, Bock SA, Branum A, et al. Second symposium on the definition and management of anaphylaxis: summary report–Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol. 2006; 117:391–7.
crossref
3. Techapornroong M, Akrawinthawong K, Cheungpasitporn W, Ruxrung- tham K. Anaphylaxis: a ten years inpatient retrospective study. Asian Pac J Allergy Immunol. 2010; 28:262–9.
4. Lim DH. Epidemiology of anaphylaxis in Korean children. Korean J Pediatr. 2008; 51:351–4.
crossref
5. Sicherer SH, Sampson HA. Food allergy: Epidemiology, pathogenesis, diagnosis, and treatment. J Allergy Clin Immunol. 2014; 133:291–307.
crossref
6. McGowan EC, Keet CA. Prevalence of self-reported food allergy in the National Health and Nutrition Examination Survey (NHANES) 2007-2010. J Allergy Clin Immunol. 2013; 132:1216–9.e5.
crossref
7. Oh JW, Pyun BY, Choung JT, Ahn KM, Kim CH, Song SW, et al. Epidemiological change of atopic dermatitis and food allergy in school-aged children in Korea between 1995 and 2000. J Korean Med Sci. 2004; 19:716–23.
crossref
8. Simons FE, Sampson HA. Anaphylaxis epidemic: fact or fiction? J Allergy Clin Immunol. 2008; 122:1166–8.
crossref
9. Dinakar C. Anaphylaxis in children: current understanding and key issues in diagnosis and treatment. Curr Allergy Asthma Rep. 2012; 12:641–9.
crossref
10. Rudders SA, Banerji A, Corel B, Clark S, Camargo CA Jr. Multicenter study of repeat epinephrine treatments for food-related anaphylaxis. Pediatrics. 2010; 125:e711–8.
crossref
11. Brown SG. Clinical features and severity grading of anaphylaxis. J Allergy Clin Immunol. 2004; 114:371–6.
crossref
12. Park HM, Noh JC, Park JH, Won YK, Hwang SH, Kim JY, et al. Clinical features of patients with anaphylaxis at a single hospital. Pediatr Allergy Respir Dis. 2012; 22:232–8.
crossref
13. Jin HJ. Anaphylaxis: diagnosis, management, and current barriers. Allergy Asthma Respir Dis. 2016; 4:79–81.
crossref
14. Kim WK. Diagnosis and treatment of food allergy in children. Pediatr Allergy Respir Dis. 2006; 16:274–83.
15. Nam SY. Food allergy; diagnosis and treatment. Pediatr Allergy Respir Dis. 2004; 14:119–26.
16. Braganza SC, Acworth JP, Mckinnon DR, Peake JE, Brown AF. Paediatric emergency department anaphylaxis: different patterns from adults. Arch Dis Child. 2006; 91:159–63.
crossref
17. Kelso JM. Pediatric emergency department anaphylaxis: different patterns from adults. Pediatrics. 2007; 120(Supplement 3):S121.
crossref
18. Brown SG, Blackman KE, Stenlake V, Heddle RJ. Insect sting anaphylaxis; prospective evaluation of treatment with intravenous adrenaline and volume resuscitation. Emerg Med J. 2004; 21:149–54.
crossref
19. Seo DH, Ye YM, Kim SC, Ban GY, Kim JH, Shin YS, et al. A single hospital survey of anaphylaxis awareness among health care providers and medical students. Allergy Asthma Respir Dis. 2016; 4:133–9.
crossref
20. Ye YM, Kim MK, Kang HR, Kim TB, Sohn SW, Koh YI, et al. Predictors of the severity and serious outcomes of anaphylaxis in korean adults: a multicenter retrospective case study. Allergy Asthma Immunol Res. 2015; 7:22–9.
crossref
21. Tejedor Alonso MA, Moro Moro M, Múgica García MV. Epidemiology of anaphylaxis. Clin Exp Allergy. 2015; 45:1027–39.
crossref
22. Koplin JJ, Martin PE, Allen KJ. An update on epidemiology of anaphylaxis in children and adults. Curr Opin Allergy Clin Immunol. 2011; 11:492–6.
crossref

Fig. 1.
The patient number of anaphylaxis registered correctly and incorrectly.
aard-5-159f1.tif
Table 1.
International Statistical Classification of Diseases 10th Revision (ICD-10) codes related anaphylaxsis
Code ICD-10 code
Anaphylaxis codes  
 Anaphylaxis T78.2B, T78.2C
 Anaphylactic shock T78.0, T78.2,T88.6
Other related codes  
 Allergy T78.4, T78.4A, T78.4B
 Food allergy T78.1
 Drug allergy T88.7, T88.7B, T88.7C, T88.7D, T88.7E, Z88
 Insect bite S-codes, T14.0G, T63.4A, W57, X23
 Angioedema T78.3
 Urticaria L28.2C, L50.0, L50.88, L50.9
Table 2.
General characteristics of anaphylaxis registered correctly and incorrectly
Characteristic Correct (n=14) Incorrect (n=119) P-value
Age (yr) 9 (1.8–12.5) 2 (0.7–9.0) 0.025
Age group (yr)     0.117
 <1 2 (14.3) 45 (37.8)  
 1–7 4 (28.6) 37 (31.1)  
 ≥7 8 (57.1) 37 (31.1)  
Male sex 6 (42.9) 69 (58.0) 0.280
Transportation to ED     0.254
 Public ambulance 2 (14.3) 6 (5.0)  
 Other medical facility 1 (7.1) 6 (5.0)  
 Individual transportation 11 (78.6) 107 (89.9)  
Elapsed time from (min)      
 Exposure to symptom onset 10 (5–65) 30 (5–120) 0.402
 Symptom onset to ED arrival 110 (57–180) 120 (60–360) 0.391
Past history of allergy 8 (57.1) 42 (35.3) 0.110
 Anaphylaxis 1 (7.1) 1 (0.8) 0.200
 Asthma 0 (0) 3 (2.5) 1.000
 Allergic rhinitis 1 (7.1) 4 (3.4) 0.432
 Atopic dermatitis 4 (28.6) 12 (10.1) 0.067
 Drug allergy 0 (0) 3 (2.5) 1.000
 Food allergy 3 (9.0) 25 (13.9) 1.000
Comorbidity 1 (7.6) 5 (4.2) 0.494

Values are presented as median (interquatile range) or number (%). ED, Emergency Department.

Mann-Whitney U-test.

Table 3.
Causes of anaphylaxis registered correctly and incorrectly
Variable Correct (n=14) Incorrect (n=119) P-value
Drug 5 (35.7) 13 (10.9) 0.024
 NSAIDs 1 (7.1) 3 (2.5) 0.363
 Penicillin 2 (14.3) 0 (0) 0.010
 Cephalosporin 2 (14.3) 1 (0.8) 0.029
 Vaccine 0 (0) 2 (1.7) 1.000
 Acetaminophen 1 (7.1) 3 (2.5) 0.363
Insect sting 0 (0) 1 (0.8) 1.000
Food 7 (50.0) 86 (72.3) 0.121
 Sea food 2 (14.3) 14 (11.8) 0.676
 Wheat 0 (0) 7 (5.6) 1.000
 Buckwheat 0 (0) 3 (2.5) 1.000
 Pupa 0 (0.0) 2 (1.7) 1.000
 Nut 2 (14.3) 5 (4.2) 0.159
 Egg 3 (21.4) 16 (13.4) 0.422
 Pork 0 (0) 3 (2.5) 1.000
 Cow milk 1 (7.1) 29 (24.4) 0.190
Idiopathic 1 (7.1) 15 (12.7) 1.000

Values are presented as number (%). NSAID, nonsteroidal anti-inflammatory drug.

Table 4.
Clinical characteristics of anaphylaxis registered correctly and incorrectly
Characteristic Correct (n=14) Incorrect (n=119) P-value
Symptoms      
 Cutaneous 13 (92.9) 118 (99.2) 0.200
Respiratory 10 (71.4) 53 (44.5) 0.088
 Cardiovascular 6 (42.9) 1 (0.8) <0.001
 Gastrointestinal 2 (14.3) 70 (58.8) 0.003
 Neurologic 2 (14.3) 1 (0.8) 0.029
Blood pressure (mmHg)      
 Systolic blood pressure 105 (96–127) 98 (95–106.5) 0.155§
 Diastolic blood pressure 72.5 (63.8–80) 61 (55.5–70) 0.017
Severe symptoms 2 (14.3) 2 (1.7) 0.055
Nonalert consciousness 1 (7.1) 0 (0.0) 0.105
ED treatment      
 O2 supply 2 (14.3) 4 (3.4) 0.121
 Fluid administration 13 (92.9) 41 (34.5) <0.001
 Antihistamine use 12 (85.7) 112 (94.1) 0.241
 Steroid use 9 (64.3) 36 (30.3) 0.016
 Epinephrine use 8 (57.1) 17 (14.3) 0.001
 Bronchodilator use 6 (42.9) 18 (15.1) 0.021

Values are presented as median number (%) or (interquatile range). ED, Emergency Department.

Mann-Whitney U-test.

Table 5.
Univariate and multivariate logistic regression analysis for factors associated with anaphylaxis registered correctly
Variable Odds ratio 95% Confidence interval P-value
Univariate logistic regression      
 Age 1.122 1.009–1.247 0.033
 Drug, as anaphylaxis cause 4.530 1.317–15.586 0.017
 Cardiovascular symptom 88.500 9.470–827.018 0.001
 Gastrointestinal symptom 0.117 0.025–0.545 0.006
 Neurologic symptom 19.667 1.659–233.166 0.018
 Diastolic blood pressure 1.050 1.009–1.094 0.018
 Fluid administration 24.732 3.125–195.758 0.002
 Steroid use 4.150 1.300–13.253 0.016
 Epinephrine use 8.000 2.467–25.943 0.001
 Bronchodilator use 4.208 1.304–13.576 0.016
Multivariate logistic regression      
 Epinephrine use 5.614 1.483–21.249 0.011
TOOLS
Similar articles